GlassScriptPhysician profile
Roxanne Swafford
NPI 1134539034
$1,758.95
in general payments reported to CMS, 2019-2025
15 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $392 · 2023: $342 · 2024: $506 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.45 |
| Education | $105.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $236.18 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $216.91 | 2021-2025 | Dupixent |
| Abbvie INC. | $205.22 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $196.98 | 2022-2025 | |
| Leo Pharma INC. | $184.38 | 2024-2025 | Adbry |
| Genzyme Corporation | $149.53 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $118.13 | 2023-2024 | |
| Amgen INC. | $103.47 | 2021-2023 | Otezla |
| Pfizer INC. | $83.40 | 2021-2023 | |
| Lilly USA, LLC | $77.03 | 2023-2024 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $62.45 | 2021-2025 | Nemluvio |
| Almirall LLC | $46.71 | 2023 | Seysara, Klisyri |
| Dermavant Sciences, INC. | $32.51 | 2023 | Vtama |
| Janssen Biotech, INC. | $29.24 | 2021 | |
| Ucb, INC. | $16.81 | 2025 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Swafford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.